胸腺肽α1注射剂联合恩替卡韦胶囊治疗乙肝肝硬化肝功能代偿期的临床研究

Clinical study on the treatment of hepatocirrhosis of hepatocirrhosis in hepatocirrhosis with chest peptide alpha 1 injection combined with entecavir capsule

目的分析肝硬化肝功能代偿期采用胸腺肽α1注射剂、恩替卡韦胶囊的治疗效果。方法将60例肝硬化功能代偿期患者分为两组,每组患者各30例,对照组采用恩替卡韦,观察组加用胸腺肽α1皮下注射,对比两组的疗效差异。结果观察组的各项临床指标改善水平优于对照组;观察组的治疗总有效率高于对照组,经检验,差异有统计学意义(P<0.05);观察组的不良反应少于对照组,经检验,差异无统计学意义(P>0.05)。讨论胸腺肽α1注射剂、恩替卡韦胶囊联合应用,可改善肝硬化肝功能代偿期诸项指标,提高疗效。

Objective Use of thymosin alpha 1 injection analysis of liver function decompensation, Entecavir Capsules＇ s therapeutic effect. Methods 60 cases of patients with decompensated cirrhosis of the liver function were divided into two groups, There were 30 patients in each group,the control group using entecavir, observation group were treated with subcutaneous injection of thymosin alpha 1, efficacy of the two groups were compared. Results The difference of the clinical indicators of the group to observe the level of improvement than the control group; the total effective rate of observation group was higher than the control group, the test was statistically significant（P 0.05）; the adverse reaction in the observation group than the control group, the test was not statistically significant（P 0.05）. Conclusion Thymosin alpha 1 injection combined with Entecavir Capsules can improve the indexes of liver function compensatory period of cirrhosis, and improve the curative effect